Cargando…

Programmed Death Ligand 1 (PD-L1) Expression in Epithelial Ovarian Cancer: A Comparison of Type I and Type II Tumors

OBJECTIVE: To examine the expression of programmed death ligand 1 (PD-L1) in type I and type II epithelial ovarian cancers (EOC) and its associations with outcomes. METHODS: Records of 132 women with EOC were reviewed. Immunostaining of PD-L1 was performed with formalin-fixed, paraffin-embedded spec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nhokaew, Wilasinee, Kleebkaow, Pilaiwan, Chaisuriya, Nipon, Kietpeerakool, Chumnan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	West Asia Organization for Cancer Prevention 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948887/ https://www.ncbi.nlm.nih.gov/pubmed/31030490 http://dx.doi.org/10.31557/APJCP.2019.20.4.1161

Ejemplares similares

Sexual behavior and infection with cervical human papillomavirus types 16 and 18
por: Itarat, Yuwadee, et al.
Publicado: (2019)

Incidence and risk factors for insufficient endometrial tissue from endometrial sampling
por: Aue-aungkul, Apiwat, et al.
Publicado: (2018)

A Case Report of High-Grade Endometrial Stromal Sarcoma: A Rare Cause of Abnormal Uterine Bleeding in a Young Woman
por: Eamudomkarn, Nuntasiri, et al.
Publicado: (2018)

Endometriosis-Associated Massive Ascites in an Asian Woman: A Case Report of a Rare Clinical Entity
por: Eamudomkarn, Nuntasiri, et al.
Publicado: (2020)

Borderline Clear Cell Adenofibroma of the Ovary
por: Kleebkaow, Pilaiwan, et al.
Publicado: (2017)

Clear Cell Carcinoma Arising in Vulvar Endometriosis
por: Buppasiri, Pranom, et al.
Publicado: (2018)

Association of Abnormal Pap Smear with Occult Cervical Stromal Invasion in Patients with Endometrial Cancer
por: Khumthong, Kewalin, et al.
Publicado: (2019)

Knowledge and Attitude toward Human Papillomavirus Infection and Vaccination among Thai Women: A Nationwide Social Media Survey
por: Likitdee, Naratassapol, et al.
Publicado: (2020)

Impact of Coexisting Uterine Adenomyosis on the Survival Outcome of Patients with Endometrial Cancer: A Retrospective Cohort Study
por: Boonlak, Sarana, et al.
Publicado: (2019)

Programmed death-ligand 1 (PD-L1) expression in various tumor types
por: Grosso, Joseph, et al.
Publicado: (2013)

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
por: Drakes, Maureen L., et al.
Publicado: (2018)

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
por: Song, Joon Seon, et al.
Publicado: (2019)

Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types
por: Scognamiglio, Giosuè, et al.
Publicado: (2016)

Quality Assessment of Websites Providing Information on Human Papillomavirus Vaccines in Thailand
por: Likitdee, Naratassapol, et al.
Publicado: (2019)

Clinical and pathological significance of programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) expression in high grade serous ovarian cancer
por: Baş, Yılmaz, et al.
Publicado: (2020)

Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma
por: Zhu, Jun, et al.
Publicado: (2017)

Prognostic Significance of Programmed Cell Death 1 (PD-1) or PD-1 Ligand 1 (PD-L1) Expression in Epithelial-Originated Cancer: A Meta-Analysis
por: Zhang, Yaxiong, et al.
Publicado: (2015)

Programmed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis
por: Delgado, Ronan Jacques Rezende, et al.
Publicado: (2019)

Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer
por: Buderath, Paul, et al.
Publicado: (2019)

In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)
por: Reddy, Vishwanatha R. A. P., et al.
Publicado: (2019)

Clinical outcomes of immunohistochemistry of the p53 Staining pattern in high-grade serous ovarian carcinoma
por: Orachum, Panarat, et al.
Publicado: (2022)

Risk of Severe Adverse Maternal and Neonatal Outcomes in Deliveries with Repeated and Primary Cesarean Deliveries versus Vaginal Deliveries: A Cross-Sectional Study
por: Kongwattanakul, Kiattisak, et al.
Publicado: (2020)

Evaluation of mobile health applications for cervical cancer in the digital marketplace
por: Kanjak, Jakkapop, et al.
Publicado: (2022)

Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma
por: Botti, Gerardo, et al.
Publicado: (2017)

Programmed death ligand 1 (PD-L1) expression in parathyroid tumors
por: Pan, Boju, et al.
Publicado: (2019)

Association of human papillomavirus type 16 long control region mutation and cervical cancer
por: Pientong, Chamsai, et al.
Publicado: (2013)

Association Between Activation of the Programmed Cell Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Pathway and Pain in Patients with Cancer
por: Zhang, Jian, et al.
Publicado: (2019)

The Prognostic Value of Plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Patients with Gastrointestinal Stromal Tumor
por: Brinch, Charlotte Margareta, et al.
Publicado: (2022)

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
por: Darb-Esfahani, Silvia, et al.
Publicado: (2015)

NLRP4 negatively regulates type I interferon response and influences the outcome in anti‐programmed cell death protein (PD)‐1/PD‐ligand 1 therapy
por: Wang, Hui, et al.
Publicado: (2022)

Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer
por: Núñez Abad, Martín, et al.
Publicado: (2022)

Prognostic and clinicopathological roles of programmed death‐ligand 1 (PD‐L1) expression in thymic epithelial tumors: A meta‐analysis
por: Koh, Hyun Min, et al.
Publicado: (2020)

Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer
por: Bari, Shahla, et al.
Publicado: (2019)

Soluble programmed death-1 (sPD-1) and programmed death ligand 1 (sPD-L1) as potential biomarkers for the diagnosis and prognosis of glioma patients
por: Liu, Shujun, et al.
Publicado: (2020)

Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics
por: Abaza, Abdelrahman, et al.
Publicado: (2023)

Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy
por: Kim, Seung Tae, et al.
Publicado: (2017)

Flow cytometry detection of cell type-specific expression of programmed death receptor ligand-1 (PD-L1) in colorectal cancer specimens
por: Saito, Akira, et al.
Publicado: (2020)

Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer
por: Kowalski, Andrzej, et al.
Publicado: (2021)

Corrigendum to “Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer”
por: Bari, Shahla, et al.
Publicado: (2019)

2241. Outcomes of Program Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer
por: Bari, Shahla, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8b0q5mhavr4v2bucbbsk9pbou1